Germline SAMD9L truncation variants trigger global translational repression.
A549 Cells
B-Lymphocytes
/ metabolism
Fatal Outcome
Female
Frameshift Mutation
Gene Expression Regulation
/ drug effects
Germ-Line Mutation
HEK293 Cells
Heterozygote
Humans
Infant, Newborn
Interferons
/ pharmacology
Myelodysplastic Syndromes
/ genetics
Protein Biosynthesis
/ genetics
Tumor Suppressor Proteins
/ genetics
Whole Genome Sequencing
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
03 05 2021
03 05 2021
Historique:
received:
09
06
2020
revised:
07
01
2021
accepted:
12
02
2021
entrez:
16
3
2021
pubmed:
17
3
2021
medline:
5
10
2021
Statut:
ppublish
Résumé
SAMD9L is an interferon-induced tumor suppressor implicated in a spectrum of multisystem disorders, including risk for myeloid malignancies and immune deficiency. We identified a heterozygous de novo frameshift variant in SAMD9L in an infant with B cell aplasia and clinical autoinflammatory features who died from respiratory failure with chronic rhinovirus infection. Autopsy demonstrated absent bone marrow and peripheral B cells as well as selective loss of Langerhans and Purkinje cells. The frameshift variant led to expression of a truncated protein with interferon treatment. This protein exhibited a gain-of-function phenotype, resulting in interference in global protein synthesis via inhibition of translational elongation. Using a mutational scan, we identified a region within SAMD9L where stop-gain variants trigger a similar translational arrest. SAMD9L variants that globally suppress translation had no effect or increased mRNA transcription. The complex-reported phenotype likely reflects lineage-dominant sensitivities to this translation block. Taken together, our findings indicate that interferon-triggered SAMD9L gain-of-function variants globally suppress translation.
Identifiants
pubmed: 33724365
pii: 211891
doi: 10.1084/jem.20201195
pmc: PMC7970252
pii:
doi:
Substances chimiques
SAMD9L protein, human
0
Tumor Suppressor Proteins
0
Interferons
9008-11-1
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R21 AI143227
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007270
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK114568
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI140530
Pays : United States
Organisme : NIH HHS
ID : S10 OD021553
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG008956
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG006493
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI145283
Pays : United States
Informations de copyright
© 2021 Allenspach et al.
Déclaration de conflit d'intérêts
Disclosures: J. Debley reported grants from NIH/NIAID during the conduct of the study and grants from NIH/NIAID outside the submitted work. No other disclosures were reported.
Références
Blood. 2012 May 10;119(19):4395-407
pubmed: 22431569
Nucleic Acids Res. 1999 Oct 1;27(19):3792-8
pubmed: 10481017
mBio. 2013 Jun 18;4(3):e00385-13
pubmed: 23781071
Virology. 2017 Mar;503:94-102
pubmed: 28157624
Int J Biol Sci. 2014 Jul 17;10(8):807-16
pubmed: 25076857
Nature. 2008 Jul 24;454(7203):523-7
pubmed: 18548002
Blood. 2017 Apr 20;129(16):2210-2212
pubmed: 28428236
Biotechniques. 2006 Sep;41(3):283-4, 286, 288 passim
pubmed: 16989088
J Clin Invest. 2020 Apr 1;130(4):1669-1682
pubmed: 31874111
Cold Spring Harb Perspect Biol. 2019 Jul 1;11(7):
pubmed: 29959193
Blood. 2017 Apr 20;129(16):2266-2279
pubmed: 28202457
Blood. 2014 Oct 30;124(18):2784-92
pubmed: 25237201
Nat Rev Genet. 2007 Sep;8(9):711-23
pubmed: 17680008
Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a012351
pubmed: 23209131
J Cell Sci. 2018 May 31;131(10):
pubmed: 29700204
J Virol. 2015 Feb;89(3):1925-31
pubmed: 25428864
EMBO Rep. 2018 Oct;19(10):
pubmed: 30224410
Cancer Res. 2017 Nov 1;77(21):e31-e34
pubmed: 29092934
Elife. 2018 Dec 06;7:
pubmed: 30520725
Immunity. 2019 Sep 17;51(3):451-464.e6
pubmed: 31471108
Cancer Cell. 2013 Sep 9;24(3):305-17
pubmed: 24029230
Virology. 2019 Mar;529:16-22
pubmed: 30641480
Cell. 2011 Nov 11;147(4):789-802
pubmed: 22056041
Adv Neurobiol. 2018;20:283-301
pubmed: 29916024
Genome Biol. 2014 Jun 26;15(6):R84
pubmed: 24970577
Leukemia. 2018 May;32(5):1106-1115
pubmed: 29535429
Nat Chem Biol. 2010 Mar;6(3):209-217
pubmed: 20118940
Biol Direct. 2017 May 25;12(1):13
pubmed: 28545555
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Carcinogenesis. 2007 Jun;28(6):1140-4
pubmed: 17347139
PLoS One. 2011 Feb 09;6(2):e16825
pubmed: 21399673
Int J Cancer. 2010 Apr 15;126(8):1982-1991
pubmed: 19830690
PLoS One. 2016 Dec 5;11(12):e0167537
pubmed: 27918590
Am J Hum Genet. 2016 Jun 2;98(6):1146-1158
pubmed: 27259050
Nat Methods. 2009 Apr;6(4):275-7
pubmed: 19305406
Cell. 2018 Mar 22;173(1):90-103.e19
pubmed: 29551269
J Virol. 2018 Nov 12;92(23):
pubmed: 30209174
Methods Mol Biol. 2017;1648:169-176
pubmed: 28766297
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
Trends Genet. 2018 Mar;34(3):218-231
pubmed: 29352613
Nucleic Acids Res. 2012 Apr;40(7):3143-51
pubmed: 22140113
JCI Insight. 2018 Jul 26;3(14):
pubmed: 30046003
Mol Cell. 2019 Jan 3;73(1):36-47.e10
pubmed: 30503772